A randomized controlled trial published in the New England Journal of Medicine concluded patients with moderate to severe refractory Crohn’s disease who received ustekinumab (Stelara ©) had a higher clinical response rate when compared to placebo. During maintenance therapy the patients also achieved slightly higher response and remission rates. How do you think this medication is going to change the treatment of Crohn’s disease? What are some lifestyle modifications  you can provide to patients who have Crohns?

For more information see NEJM.